Oxford Biomedica (LON:OXB) Shares Break Below Two Hundred Day Moving Average – Here’s What Happened

Oxford Biomedica plc (LON:OXB)’s stock price crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of GBX 567.15 and traded as low as GBX 513. Oxford Biomedica shares last traded at GBX 521, with a volume of 147,276 shares trading hands.

Wall Street Analyst Weigh In

A number of analysts have issued reports on OXB shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 595 target price on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Royal Bank Of Canada reissued an “outperform” rating and set a GBX 900 price target on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Oxford Biomedica currently has an average rating of “Moderate Buy” and an average target price of GBX 613.32.

Oxford Biomedica Stock Performance

The firm has a 50 day simple moving average of GBX 495.77 and a 200-day simple moving average of GBX 567.15. The company has a debt-to-equity ratio of 273.08, a current ratio of 2.21 and a quick ratio of 1.67. The company has a market cap of £630.66 million, a price-to-earnings ratio of -16.30 and a beta of 1.09.

Oxford Biomedica (LON:OXB) last posted its earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) EPS for the quarter. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%. As a group, analysts predict that Oxford Biomedica plc will post -31.08 EPS for the current fiscal year.

Insider Buying and Selling at Oxford Biomedica

In other Oxford Biomedica news, insider Roch Doliveux acquired 20,250 shares of the business’s stock in a transaction that occurred on Wednesday, September 23rd. The stock was purchased at an average cost of GBX 505 per share, with a total value of £102,262.50. Corporate insiders own 25.83% of the company’s stock.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.